NEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) — Cowen Inc. (NASDAQ:COWN) (“Cowen” or the “Company”) will host a conference call on Thursday, February 11, 2021 at 9:00 AM ET to discuss the Company’s financial results for the fourth quarter of 2020.
The conference call will be broadcast live via this link on the Investor Relations section of Cowen’s website. Please access the link at least 15 minutes prior to the call to register. A replay will be available on the Investor Relations section of Cowen’s website approximately two hours after completion of the conference call at investor.cowen.com/investor-calls.
Investors can also access the conference call by dialing 1-855-760-0961 (1-631-485-4850 outside the U.S.). The passcode for the call is 9894979. A recording of the conference call will be available for one week beginning at 12:00 PM ET on February 11 by dialing 1-855-859-2056 (1-404-537-3406 outside the U.S.) and entering passcode 9894979.
About Cowen Inc.
Cowen Inc. (“Cowen” or the “Company”) is a diversified financial services firm offering investment banking services, equity and credit research, sales and trading, prime brokerage, global clearing, commission management services and actively managed alternative investment products. Cowen Inc. focuses on delivering value-added capabilities to our clients in order to help them outperform. Founded in 1918, the firm is headquartered in New York and has offices worldwide. Learn more at Cowen.com.
Investor Relations Contact:
Cowen Inc.
J.T. Farley
1-646-562-1056
james.farley@cowen.com
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…